TTNP Stock UPDATES Titan Pharma Inc (TTNP) 0.6800 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Titan Pharma Inc (TTNP) 0.6800 $TTNP

Titan Pharmaceuticals Announces Second Quarter 2014 Financial Results
Marketwire - Wed Aug 13, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence and other serious medical disorders, today reported financial results for the second quarter ended June 30, 2014.

Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2014 Financial Results
Marketwire - Thu Aug 07, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Thursday, Aug. 14, 2014 to discuss the company's financial results as of June 30, 2014. The call will be hosted by Sunil Bhonsle, president; Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the second quarter and financial results will be included in a press release to be issued prior to the call.

Titan Pharmaceuticals Announces First Patient Enrollment in Clinical Study of Probuphine for Opioid Dependence
Marketwire - Mon Jul 21, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced enrollment of the first patients in the Phase 3 clinical study to support resubmission of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The study, which is expected to be completed by the middle of 2015, is designed to address key questions posed by the U.S. Food and Drug Administration (FDA) in its complete response letter last year after review of the original NDA. Titan's partner Braeburn Pharmaceuticals is sponsoring the trial and anticipates resubmission of the NDA to the FDA in late 2015.

Highline Research Advisors Initiates on Titan Pharmaceuticals with a Buy Rating
Thomson Reuters ONE - Mon Jul 07, 9:44AM CDT
SAN FRANCISCO - July 7, 2014 -Michael Higgins from Highline Research Advisors, part of Financial Entrepreneur Platform at Merriman Capital, Inc. ("Merriman" , a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it has initiated equity research coverage of Titan Pharmaceuticals, Inc. (OTCQB: TTNP) with a Buy rating and a $3.00 price target.

Titan Pharmaceuticals Receives Notice of Allowance for Patent of Implantable Polymeric Device for Sustained Release of Dopamine Agonists
Marketwire - Mon Jun 09, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence and other serious medical disorders, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering the sustained release of dopamine agonists utilizing ProNeura(TM), Titan's proprietary long-term drug delivery technology. The patent, titled "Implantable Polymeric Device for Sustained Release of a Dopamine Agonist," provides intellectual property protection for the company's development program of ProNeura for Parkinson's disease and carries a patent term to at least 2024. Similar patents have been issued in Europe, Australia, Canada, Japan, Korea, Mexico, New Zealand, South Africa and Hong Kong, and patent applications are pending in Israel, India and China.

Titan Pharmaceuticals Announces Fourth Quarter and Year End 2013 Financial Results
Marketwire - Mon Mar 31, 6:02AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today reported financial results for the fourth quarter and year ended December 31, 2013.

Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Wed Mar 26, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Tuesday, April 1, 2014 to discuss the company's financial results as of December 31, 2013. The call will be hosted by Sunil Bhonsle, president; Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman.

Titan Pharmaceuticals Announces Agreement in Principle on Path Forward for Probuphine Clinical Study
Marketwire - Mon Mar 03, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that the company and its partner, Braeburn Pharmaceuticals, have agreed in principle with the U.S. Food and Drug Administration (FDA) on the design of a clinical study in support of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The proposed clinical study will be a randomized, double blind and double dummy design that will provide information for a non-inferiority comparison of a six-month treatment with a dose of four Probuphine implants to treatment with 8mg or less of an approved daily dosed sublingual formulation of buprenorphine. Details of the study, including size and the data analysis plan, will be established following the FDA's review of a complete study protocol, which Braeburn expects to submit within the next two weeks.

CSE: 2014-0205-Name and Symbol Change-Synergy Acquisition Corp. (QMP)
Marketwire Canada - Wed Feb 12, 10:20AM CST
Synergy Acquisition Corp. has announced a name change to Genius Properties Ltd.

Spectra7 Announces Promotion Of Melissa Chee To Vice President Of Corporate Marketing And Product Management
PR Newswire - Tue Feb 04, 8:00AM CST
(TSX-V:SEV) Spectra7 Microsystems Inc. ("Spectra7" , a high performance analog semiconductor company delivering unprecedented speed, resolution and signal fidelity to consumer and wireless infrastructure products, today announced that Melissa Chee has been promoted to Vice President of Corporate Marketing and Product Management for the Company.

SecurityMetrics PCI Suite Named Finalist in Info Security Products Guide Global Excellence Awards
PR Newswire - Thu Jan 16, 12:18PM CST
Info Security Products Guide, the industry's leading information security research and advisory guide, has named SecurityMetrics PCI Suite a finalist for the 10th Annual 2014 Global Excellence Awards in the PCI Compliance category. These prestigious global awards recognize security and IT vendors with advanced products and solutions that help set the bar higher for others in all areas of security and technology.

Esri's Location Platform Brings the Power of Place to Microsoft Dynamics CRM
PR Newswire - Tue Jan 07, 1:45PM CST
Esri today announced the release of an enhanced Esri Maps for Microsoft Dynamics CRM. The software adds new analytical perspectives for retailers across the omni-channel. From a single store to the entire supply-chain, users can collaborate to author and share analytical intelligence on customers, stores, products, markets, and the competition with a wealth of demographic data for 120 countries.

Titan Pharmaceuticals Receives Official Minutes From FDA Meeting on Probuphine New Drug Application
Marketwire - Mon Dec 23, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced the receipt of the official minutes (the "Minutes" from a Type C meeting with the U.S. Food and Drug Administration (FDA) on November 19, 2013 to discuss the Complete Response Letter (CRL) to its New Drug Application (NDA) for Probuphine(R), an investigational subdermal implant for the maintenance treatment of opioid dependence in adult patients. Per the Minutes, the FDA emphasized its commitment to working with Titan and its partner, Braeburn Pharmaceuticals, to pursue a reasonable path to approval, and all parties agreed that seeking an indication in individuals stabilized on 8 mg/day or less of sublingual buprenorphine (SL BPN) may be a suitable approval pathway for Probuphine. Titan and Braeburn proposed the revised indication following a review of the FDA's comments on the briefing material and to address one of the primary concerns in the CRL regarding dose adequacy among the original study population (newly inducted patients maintained at 12-16 mg SL BPN/day). The FDA maintained the need for clinical data in this patient population as a requirement for approval, stipulating that the study "need not be large," "be adequate and well-controlled," and "must support labeling for the duration of treatment (6 months)." Titan and Braeburn are working with experts in the field to develop a clinical study design for submission to the FDA within the next few weeks.

Cambridge University Press picks DayNine Consulting management tool
M2 - Wed Dec 18, 8:25AM CST
Workday (NYSE: WDAY) services partner DayNine Consulting said it was selected by Cambridge University Press to deploy its Workday Human Capital Management solution.

Titan Pharmaceuticals Announces Submission of FDA Meeting Request Regarding Probuphine
Marketwire - Wed Sep 04, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced the submission of a Type B meeting request to the U.S. Food and Drug Administration (FDA) to discuss Probuphine(R), the company's investigational subdermal implant designed to deliver continuous, blood levels of buprenorphine for six months following a single treatment.

Titan Pharmaceuticals Announces Publication of Phase 3 Probuphine Data in Addiction
Marketwire - Tue Aug 13, 4:03PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that data from its previously completed and announced Phase 3 placebo- and active drug-controlled confirmatory clinical study of Probuphine(R), evaluating the safety and efficacy of its subdermal implant for the maintenance treatment of opioid dependence in adult patients, were published online in the journal Addiction. The paper is expected to appear in a future print issue of the journal.

Titan Pharmaceuticals Announces Amendment to Partnership With Braeburn Pharmaceuticals
Marketwire - Wed May 29, 3:05PM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has entered into an amendment to its license agreement with Braeburn Pharmaceuticals Sprl for the exclusive commercialization rights in the U.S. and Canada to the investigational product Probuphine(R), a novel, subdermal implant and the first long-acting product designed to deliver six months of the drug buprenorphine following a single treatment. The amendment primarily modifies certain of the agreement's termination provisions by providing Braeburn the right to terminate the license in the event significant additional clinical work or a material change to the product label will be required by the U.S. Food and Drug Administration (FDA) as a condition to approval of the New Drug Application (NDA) or if the NDA is not approved by June 30, 2014.

Titan Pharmaceuticals Inc swings to net income of USD6.0m for Q1 2013
M2 - Thu May 16, 8:30AM CDT
Biopharmaceutical company Titan Pharmaceuticals Inc (OTCBB:TTNP) stated on Wednesday its net income of USD6.0m (USD0.08 per share) for the first quarter ended 31 March 2013.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 79

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
VIGGO’s Mix1Pro Tests Practical Commercial Cleaning

Updated Category News Views 53

A cleaning robot earns its keep in the ugly corners, not under convention-center lights. VIGGO used the ISSA Show North America gathering in Las Vegas, held November 17–19, 2026, to introduce the Mix1Pro, a compact commercial machine aimed at indoor facilities below 53,800 square feet. That target matters. Smaller, messier sites are where autonomy can look terrific on a...

Continue Reading
Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 44

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 25

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 51

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 31

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 464

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 113

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 66

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading

Top 5 Most Recently Viewed Articles

ProQR Initiates Presentation at Citizens Life Sciences Event

Updated Category News Views 132

ProQR Therapeutics to Present at Citizens Life Sciences Conference ProQR Therapeutics N.V. (Nasdaq: PRQR), dedicated to transforming lives through innovative RNA therapies, has announced a presentation scheduled for the Citizens Life Sciences Conference in New York City. The event will take place on a specified date, and ProQR’s management team is set to delve into...

Continue Reading
Man Group PLC Highlights Positions in American Axle & Manufacturing

Updated Category News Views 113

Understanding Man Group PLC's Position in American Axle & Manufacturing Man Group PLC is making headlines as it reveals significant details regarding its position in American Axle & Manufacturing Holdings, Inc. This disclosure showcases the firm's strategic interests in relevant securities, representing a noteworthy percentage that meets regulatory requirements. Key...

Continue Reading
Ocular Therapeutix Transforms Brand with Focus on Retina Care

Updated Category News Views 296

Ocular Therapeutix Modernizes Brand to Emphasize Retina Health In a significant move aimed at aligning its identity with its mission, Ocular Therapeutix, Inc. (NASDAQ: OCUL) has launched an innovative corporate branding initiative along with a new website. This transition marks a pivotal shift towards a dedicated focus on retinal health, showcasing the company’s...

Continue Reading
Raytron's Innovative OGI Cameras Enhance Ozone Layer Protection

Updated Category News Views 195

Raytron's Commitment to Ozone Layer Preservation As the International Day for the Preservation of the Ozone Layer approaches, global attention focuses on looming threats to atmospheric recovery, particularly from greenhouse gases that continue to pose significant risks. While advancements have been made to eliminate CFCs under the Montreal Protocol, the ongoing rise in...

Continue Reading
Booz Allen Hamilton's CFO Makes Strategic Stock Sale Decision

Updated Category News Views 119

Booz Allen Hamilton Holding Corp. (NYSE: BAH) just served up some intriguing corporate moves with its Executive Vice President and Chief Financial Officer, Matthew Calderone, making headlines. He recently sold off 3,865 shares of the company's Class A Common Stock for a substantial total of $618,400. That kind of action doesn’t happen in a vacuum; it's a signal that...

Continue Reading